Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Receivables: 2019-2025

Historic Change in Receivables for Ascendis Pharma A (ASND) over the last 7 years, with Sep 2025 value amounting to -$29.1 million.

  • Ascendis Pharma A's Change in Receivables fell 191.63% to -$29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.7 million, marking a year-over-year decrease of 5604.26%. This contributed to the annual value of -$128.4 million for FY2024, which is 264.06% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Change in Receivables is -$29.1 million, which was up 46.39% from -$54.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Change in Receivables ranged from a high of $103.1 million in Q1 2025 and a low of -$133.4 million during Q4 2024.
  • In the last 3 years, Ascendis Pharma A's Change in Receivables had a median value of -$12.3 million in 2024 and averaged -$12.9 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Change in Receivables spiked by 2,840.90% in 2021, and later tumbled by 3,786.48% in 2023.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Change in Receivables stood at $3.0 million in 2021, then crashed by 284.63% to -$5.6 million in 2022, then crashed by 64.71% to -$9.2 million in 2023, then plummeted by 1,354.25% to -$133.4 million in 2024, then slumped by 191.63% to -$29.1 million in 2025.
  • Its Change in Receivables stands at -$29.1 million for Q3 2025, versus -$54.3 million for Q2 2025 and $103.1 million for Q1 2025.